Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Cytek Biosciences, Inc. (CTKB : NSDQ)

• Company Description    Cytek Biosciences Inc provides cell analysis solutions. The company developed high-resolution, high-content and high-sensitivity cell analysis technology called Full Spectrum Profiling. Cytek Biosciences Inc is based in FREMONT, Calif. Number of Employees: 702

• Price / Volume Information    Yesterday's Closing Price: $4.62 Daily Weekly Monthly 20 Day Moving Average: 693,378 shares Shares Outstanding: 129.98 (millions) Market Capitalization: $600.52 (millions) Beta: 1.18 52 Week High: $6.18 52 Week Low: $3.28 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week -2.53% -1.84% 12 Week 12.96% 10.57% Year To Date -8.51% -18.39%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 47215 Lakeview Blvd. - Fremont,CA 94538 USA ph: 877-922-9835 fax: - investors@cytekbio.com https://cytekbio.com

• General Corporate Information    Officers Wenbin Jiang - President and Chief Executive Officer William McCombe - Chief Financial Officer Ming Yan - Chief Technology Officer and Director Jack Ball - Director Richard Chin - Director Peer Information Cytek Biosciences, Inc. (CORR.) Cytek Biosciences, Inc. (RSPI) Cytek Biosciences, Inc. (CGXP) Cytek Biosciences, Inc. (BGEN) Cytek Biosciences, Inc. (GTBP) Cytek Biosciences, Inc. (RGRX) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-BIOMED/GENE Sector: Medical CUSIP: 23285D109 SIC: 3826 Fiscal Year Fiscal Year End: December Last Reported Quarter: 06/01/26 Next Expected EPS Date: 11/04/26 Share - Related Items Shares Outstanding: 129.98 Most Recent Split Date: (:1) Beta: 1.18 Market Capitalization: $600.52 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $-0.05 Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $-0.30 Payout Ratio: Number of Estimates in the Fiscal Year Consensus: 1.00 Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 11/04/26

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: 1.85 Price/Cash Flow: - Price / Sales: 2.91 EPS Growth vs. Year Ago Period: -125.00% vs. Previous Quarter: 40.00% Sales Growth vs. Year Ago Period: 5.57% vs. Previous Quarter: 9.07% ROE 06/30/26 - -12.40 03/31/26 - -10.07 12/31/25 - -7.70 ROA 06/30/26 - -9.17 03/31/26 - -7.56 12/31/25 - -5.89 Current Ratio 06/30/26 - 4.48 03/31/26 - 4.69 12/31/25 - 5.04 Quick Ratio 06/30/26 - 3.86 03/31/26 - 4.07 12/31/25 - 4.42 Operating Margin 06/30/26 - -20.55 03/31/26 - -17.58 12/31/25 - -14.11 Net Margin 06/30/26 - -38.98 03/31/26 - -36.25 12/31/25 - -33.02 Pre-Tax Margin 06/30/26 - -19.75 03/31/26 - -17.61 12/31/25 - -14.81 Book Value 06/30/26 - 2.49 03/31/26 - 2.54 12/31/25 - 2.67 Inventory Turnover 06/30/26 - 1.91 03/31/26 - 1.98 12/31/25 - 1.99 Debt-to-Equity 06/30/26 - 0.00 03/31/26 - 0.00 12/31/25 - 0.00 Debt-to-Capital 06/30/26 - 0.08 03/31/26 - 0.12 12/31/25 - 0.15

Powered by Zacks Investment Research ©